Evidence mapPaperPMID 37154584Full record

ArticleThe Prostate2023

Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.

Michael T Marrone, Anna E Prizment, David Couper, Kenneth R Butler, Brad C Astor, Corinne E Joshu, Elizabeth A Platz, Alison M Mondul

Open access · bronzeAbstract read
In one paragraph

Article in The Prostate, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Michael T MarroneDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-1568-9499
Anna E PrizmentDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
David CouperDepartment of Biostatistics, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Kenneth R ButlerDepartment of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID 0000-0003-3198-8835
Brad C AstorDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Corinne E JoshuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-5100-172X
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Alison M MondulDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Johns Hopkins University · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Mississippi Medical Center · USUniversity of North Carolina at Chapel Hill · USUniversity of Wisconsin–Madison · US

Funding

Translational Research Central ServicesP30CA006973 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$45.1M
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIPT32CA009314 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$2.0M
Treg functional changes: a novel immune regulatory effect underlying the benefit of statin drug use on lethal prostate cancerR00CA246097 · MEDICAL UNIVERSITY OF SOUTH CAROLINA · 2025 to 2025
$223k
NCI NIH HHS K99 CA246097NCI NIH HHS P30 CA006973NCI NIH HHS R00 CA246097NCI NIH HHS T32 CA009314NCI NIH HHS T32 CA09314NCI NIH HHS U01 CA164975NHLBI NIH HHS HHSN268201700001CNHLBI NIH HHS HHSN268201700001INHLBI NIH HHS HHSN268201700002CNHLBI NIH HHS HHSN268201700002INHLBI NIH HHS HHSN268201700003CNHLBI NIH HHS HHSN268201700003INHLBI NIH HHS HHSN268201700004CNHLBI NIH HHS HHSN268201700004INHLBI NIH HHS HHSN268201700005CNHLBI NIH HHS HHSN268201700005I
6 · The paper itself

Abstract

backgroundCholesterol reduction is considered a mechanism through which cholesterol-lowering drugs including statins are associated with a reduced aggressive prostate cancer risk. While prior cohort studies found positive associations between total cholesterol and more advanced stage and grade in White men, whether associations for total cholesterol, low (LDL)- and high (HDL)-density lipoprotein cholesterol, apolipoprotein B (LDL particle) and A1 (HDL particle), and triglycerides are similar for fatal prostate cancer and in Black men, who experience a disproportionate burden of total and fatal prostate cancer, is unknown.

methodsWe conducted a prospective study of 1553 Black and 5071 White cancer-free men attending visit 1 (1987-1989) of the Atherosclerosis Risk in Communities Study. A total of 885 incident prostate cancer cases were ascertained through 2015, and 128 prostate cancer deaths through 2018. We estimated multivariable-adjusted hazard ratios (HRs) of total and fatal prostate cancer per 1-standard deviation increments and for tertiles (T1-T3) of time-updated lipid biomarkers overall and in Black and White men.

resultsGreater total cholesterol concentration (HR per-1 SD = 1.25; 95% CI = 1.00-1.58) and LDL cholesterol (HR per-1 SD = 1.26; 95% CI = 0.99-1.60) were associated with higher fatal prostate cancer risk in White men only. Apolipoprotein B was nonlinearly associated with fatal prostate cancer overall (T2 vs. T1: HR = 1.66; 95% CI = 1.05-2.64) and in Black men (HR = 3.59; 95% CI = 1.53-8.40) but not White men (HR = 1.13; 95% CI = 0.65-1.97). Tests for interaction by race were not statistically significant.

conclusionsThese findings may improve the understanding of lipid metabolism in prostate carcinogenesis by disease aggressiveness, and by race while emphasizing the importance of cholesterol control.

Indexed as

CholesterolProstatic NeoplasmsApolipoproteinsCholesterol, HDLHumansMaleProspective StudiesRisk FactorsTriglyceridesApolipoproteinsCholesterolCholesterol, HDLTriglyceridescohortlipidsmetabolismprostate cancerrisktotal cholesterol

Identifiers

PMID37154584
PMCPMC12478469
OpenAlexW4375861259

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.